Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT02159495 trial: what clinicians have said so far
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
- NCT02159495 ↗
- Active, not recruiting
- City of Hope Medical Center
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT02159495 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02159495 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With CD123+ Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Adult Acute Myeloid Leukemia in Remission; Acute Biphenotypic Leukemia; Early Relapse of Acute Myeloid Leukemia; Late Relapse of Acute Myeloid Leukemia; Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Blastic Plasmacytoid Dendritic Cell Neoplasm; Acute Myeloid Leukemia; Adult Acute Lymphoblastic Leukemia; Interleukin-3 Receptor Subunit Alpha Positive; Minimal Residual Disease; Refractory Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
- Interventions
- cyclophosphamide; Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes; laboratory biomarker analysis; Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes; Fludarabine Phosphate
- Arms
- Treatment (lymphodepletion, T-cell immunotherapy) · Experimental
- Enrollment
- 31
- Primary outcomes
- Dose-limiting toxicity (DLT) defined as any grade 3 or higher toxicity as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Incidence of adverse events as assessed by NCI CTCAE version 4.0
- Disease response (CR or CRi)
- Sponsor
- City of Hope Medical Center with National Cancer Institute (NCI), Mustang Bio, Inc.
- Start
- Dec 15, 2015
- Primary completion
- Jul 14, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT02159495 · updated Aug 26, 2026
Publications
linked from the registry- Budde LE, Del Real MM, Song J, Stiller T, Wang Y, Aribi A, Sandhu K, Nakamura R, Marcucci EC, Wu JJ, Ng K, Clark MC, Wood B, Wagner JR, Paul J, Brown CE, Stein A, Marcucci G, Blanchard MS, Palmer J, Forman SJ. A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm. J Hematol Oncol. 2026 Aug 7;19(1):68. doi: 10.1186/s13045-026-01833-3. PubMed 42681647